Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was ...
CAPLYTA net product sales grew to $199.2 million, representing a 51%increase over the same period in 2023Full year 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback